| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5546144 | Current Opinion in Virology | 2017 | 7 Pages |
Abstract
The rVSV-ZEBOV vaccine is currently the only Ebola vaccine with demonstrated clinical efficacy in a ring-vaccination clinical trial. It has been shown to be reactogenic but immunogenic and safe in several Phase I clinical studies. However, its mechanisms of protection are unknown and available immunogenicity data are mostly limited to classical serological analysis; it is now of paramount importance to apply cutting-edge technologies, including transcriptomic and metabolomic analyses, and to perform integrative analyses with standard serology and clinical data to comprehensively profile the rVSV-ZEBOV immune signature.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Donata Medaglini, Claire-Anne Siegrist,